Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jennifer Dorcas Hwang, Mateus Trinconi Cunha, Molly Russell, Gretchen Pardo, Hisham Alsharif, Fahad Rind, Emile Gogineni, Simeng Zhu, David Joseph Konieczkowski, John C. Grecula, Darrion L. Mitchell, Lauren Miller, Catherine Haring, Nolan Seim, Kyle VanKoevering, Stephen Kang, James William Rocco, Dukagjin Blakaj, Priyanka Bhateja, Marcelo Raul Bonomi
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162524016
Cites:
Cited by:
Related to: